FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APP	OMB APPROVAL				
OMB Number:	MB Number: 3235-0104				
Estimated average burden					
hours per response:	0.5				

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

2. Date of Event Requiring Statement (Month/Day/Year) 02/12/2015 3. Issuer Name and Ticker or Trading Symbol EYEGATE PHARMACEUTICALS INC [EYEG]									
		(Check all applicable)		r (Mon	5. If Amendment, Date of Original Filed (Month/Day/Year)				
		Officer (give title below)	Other (spe below)	Appli	Individual or Joint/Group Filing (Check pplicable Line) X Form filed by One Reporting Person				
					Form filed by Reporting Pe	y More than One erson			
Table I - Non-Derivative Securities Beneficially Owned									
1. Title of Security (Instr. 4)			3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)		re of Indirect Beneficial Ownership i)				
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)									
2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise	5. Ownership Form:	6. Nature of Indirect Beneficial Ownership (Instr. 5)			
Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Derivative Security	or Indirect (I) (Instr. 5)				
(1)	11/01/2022	Common Stock	8,355	0.65	D				
	Table I - Nor Table II - I e.g., puts, cal 2. Date Exercisable Date Exercisable	Table II - Non-Derivat Table II - Derivative e.g., puts, calls, warra 2. Date Exercisable and Expiration Date (Month/Day/Year) Date Exercisable Expiration Date	Table I - Non-Derivative Securities Beneficially Owned (Instr. 4) Table II - Derivative Securities Beneficially Owned (Instr. 4) Table II - Derivative Securities Beneficially Owned (Instr. 4) Table II - Derivative Securities Beneficially Owned (Instr. 4) Table II - Derivative Securities Beneficially Owned (Instr. 4) Table II - Derivative Securities Beneficially Owned (Instr. 4) Table II - Derivative Securities Beneficially Owned (Instr. 4) Table II - Derivative Securities Beneficially Owned (Instr. 4) Table II - Derivative Securities Beneficially Owned (Instr. 4) Table II - Derivative Securities Beneficially Owned (Instr. 4) Table II - Derivative Securities Beneficially Owned (Instr. 4) Table II - Derivative Securities Beneficially Owned (Instr. 4) Table II - Derivative Securities Beneficially Owned (Instr. 4) Table II - Derivative Securities Beneficially Owned (Instr. 4) Table II - Derivative Securities Beneficially Owned (Instr. 4)	Table I - Non-Derivative Securities Beneficially Owned Penerically	EYEGATE PHARMACEUTICALS INC	EYEGATE PHARMACEUTICALS INC EYEG			

Explanation of Responses:

1. The option became exercisable as to 33% of the shares underlying the option on Nov. 1, 2013 with 2.79% of the shares underlying the option vesting monthly thereafter.

Remarks:

*Signed under power of attorney on behalf of Reporting Person

/s/ Authorized Signatory* 02/12/2015

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.